The DOI matches its Crossref record; 120 of the 120 references it cites were found in a registry or an index.
CPT1A-mediated Fat Oxidation, Mechanisms, and Therapeutic Potential
Abstract
Energy homeostasis during fasting or prolonged exercise depends on mitochondrial fatty acid oxidation (FAO). This pathway is crucial in many tissues with high energy demand and its disruption results in inborn FAO deficiencies. More than 15 FAO genetic defects have been currently described, and pathological variants described in circumpolar populations provide insights into its critical role in metabolism. The use of fatty acids as energy requires more than 2 dozen enzymes and transport proteins, which are involved in the activation and transport of fatty acids into the mitochondria. As the key rate-limiting enzyme of FAO, carnitine palmitoyltransferase I (CPT1) regulates FAO and facilitates adaptation to the environment, both in health and in disease, including cancer. The CPT1 family of proteins contains 3 isoforms: CPT1A, CPT1B, and CPT1C. This review focuses on CPT1A, the liver isoform that catalyzes the rate-limiting step of converting acyl-coenzyme As into acyl-carnitines, which can then cross membranes to get into the mitochondria. The regulation of CPT1A is complex and has several layers that involve genetic, epigenetic, physiological, and nutritional modulators. It is ubiquitously expressed in the body and associated with dire consequences linked with genetic mutations, metabolic disorders, and cancers. This makes CPT1A an attractive target for therapeutic interventions. This review discusses our current understanding of CPT1A expression, its role in heath and disease, and the potential for therapeutic opportunities targeting this enzyme.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fundamentals of Cancer Metabolism
DeBerardinis, R. J., & Chandel, N. S. (2016) · Science Advances · doi:10.1126/sciadv.1600200 · Cited by 3,013 · cited 1×
“The ability to survive harsh environments is a characteristic of successful cancer cells (122,123).”
BackgroundPeroxisome proliferator–activated receptor α mediates the adaptive response to fasting
Kersten, S., Seydoux, J., Peters, J. M., Gonzalez, F. J., Desvergne, B., & Wahli, W. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6223 · Cited by 1,649
The Mitochondrial Carnitine Palmitoyltransferase System — From Concept to Molecular Analysis
McGarry, J. D., & Brown, N. F. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.00001.x · Cited by 1,616
PGC-1 coactivators: inducible regulators of energy metabolism in health and disease
Finck, B. N. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27794 · Cited by 1,432
Leone, T. C., Weinheimer, C. J., & Kelly, D. P. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.13.7473 · Cited by 943
The Biochemistry and Physiology of Mitochondrial Fatty Acid β-Oxidation and Its Genetic Disorders
Houten, S. M., Violante, S., Ventura, F. V., & Wanders, R. J. A. (2016) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021115-105045 · Cited by 920
Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2
Abu-Elheiga, L., Matzuk, M. M., Abo-Hashema, K. A. H., & Wakil, S. J. (2001) · Science · doi:10.1126/science.1056843 · Cited by 903
A possible role for malonyl-CoA in the regulation of hepatic fatty acid oxidation and ketogenesis.
McGarry, J. D., Mannaerts, G. P., & Foster, D. W. (1977) · Journal of Clinical Investigation · doi:10.1172/jci108764 · Cited by 736 · cited 1×
“Dennis McGarry and Daniel Foster published a seminal paper in 1977 noting the surprising finding that malonyl-CoA, the substrate for fatty acid synthesis, was also the inhibitor of fatty acid oxidation (69).”
BackgroundSamudio, I., Harmancey, R., Fiegl, M., Kantarjian, H., Konopleva, M., Korchin, B., Kaluarachchi, K., Bornmann, W., Duvvuri, S., Taegtmeyer, H., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci38942 · Cited by 709
Malonyl-CoA, fuel sensing, and insulin resistance
Ruderman, N. B., Saha, A. K., Vavvas, D., & Witters, L. A. (1999) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1999.276.1.e1 · Cited by 650
Cited by
NADPH homeostasis in cancer: functions, mechanisms and therapeutic implications
Ju, H.-Q., Lin, J.-F., Tian, T., Xie, D., & Xu, R.-H. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00326-0 · Cited by 581
Metabolic regulation of the immune system in health and diseases: mechanisms and interventions
Hu, T., Liu, C.-H., Lei, M., Zeng, Q., Li, L., Tang, H., & Zhang, N. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01954-6 · Cited by 383
Miguel, V., Tituaña, J., Herrero, J. I., Herrero, L., Serra, D., Cuevas, P., Barbas, C., Puyol, D. R., Márquez-Expósito, L., Ruiz-Ortega, M., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci140695 · Cited by 344
Wu, D., Spencer, C. B., Ortoga, L., Zhang, H., & Miao, C. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103194 · Cited by 310
ACSL family: The regulatory mechanisms and therapeutic implications in cancer
Quan, J., Bode, A. M., & Luo, X. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174397 · Cited by 306
Mitochondrial CPT1A: Insights into structure, function, and basis for drug development
Liang, K. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1160440 · Cited by 156
“CPT1A is a significant therapeutic target due to its important function in a variety of illnesses (Schlaepfer and Joshi, 2020).”
BackgroundLinking Metabolic Reprogramming, Plasticity and Tumor Progression
Shuvalov, O., Daks, A., Fedorova, O., Petukhov, A., & Barlev, N. (2021) · Cancers · doi:10.3390/cancers13040762 · Cited by 63
Acetyl-CoA metabolism as a therapeutic target for cancer
Chen, G., Bao, B., Cheng, Y., Tian, M., Song, J., Zheng, L., & Tong, Q. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115741 · Cited by 54
Joshi, M., Kim, J., D’Alessandro, A., Monk, E., Bruce, K., Elajaili, H., Nozik-Grayck, E., Goodspeed, A., Costello, J. C., & Schlaepfer, I. R. (2020) · Cancers · doi:10.3390/cancers12113431 · Cited by 54
“CPT1A fuels lipid beta-oxidation in PCa cells by producing acyl-carnitines in the mitochondria [9].”
BackgroundSelf-citationAcylated Ghrelin as a Multi-Targeted Therapy for Alzheimer's and Parkinson's Disease
Reich, N., & Hölscher, C. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.614828 · Cited by 48
Jiang, C., Zhu, Y., Chen, H., Lin, J., Xie, R., Li, W., Xue, J., Chen, L., Chen, X., & Xu, S. (2023) · Cell Death & Disease · doi:10.1038/s41419-023-06181-5 · Cited by 36
Sáez-Orellana, F., Leroy, T., Ribeiro, F., Kreis, A., Leroy, K., Lalloyer, F., Baugé, E., Staels, B., Duyckaerts, C., Brion, J.-P., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.150099 · Cited by 29
Wang, Y., Bian, X., Wan, M., Dong, W., Gao, W., Yao, Z., & Guo, C. (2024) · Nutrition & Metabolism · doi:10.1186/s12986-023-00775-8 · Cited by 20
“The protein expressions of FAS, ATGL and CPT1, three critical enzymes in fatty acid synthesis, triglyceride hydrolysis, and fatty acid oxidation were detected in the liver using ELISA technique [29–31].”
MethodZhu, R., Gu, S., Tao, Y., & Zhang, Y. (2025) · Discover Oncology · doi:10.1007/s12672-025-02686-x · Cited by 8
Regulation of astrocyte metabolism by mitochondrial translocator protein 18 kDa
Firth, W., Robb, J. L., Stewart, D., Pye, K. R., Bamford, R., Oguro‐Ando, A., Beall, C., & Ellacott, K. L. J. (2024) · Journal of Neurochemistry · doi:10.1111/jnc.16089 · Cited by 5
Metadata
- Authors
- Schlaepfer, I. R., & Joshi, M.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2020-01-04
- Volume
- 161
- Issue
- 2
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2997840987
- Cited by
- 732
- References
- 120
- FWCI
- 40.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.